{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-084743","form_type":"8-K","ticker":"NWBO","cik":"0001072379","company_name":"NORTHWEST BIOTHERAPEUTICS INC","filed_at":"2026-07-17T23:48:55+00:00","discovered_at":"2026-07-20T10:05:00.260608+00:00","generated_at":"2026-07-20T10:05:40.678855+00:00","sec_items":["7.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"NWBO refutes false rumors of MHRA rejection; MHRA confirms DCVax-L MAA still under review","bullets":["MHRA confirmed DCVax-L MAA for glioblastoma remains under initial review, not refused, withdrawn, or appealed.","Company categorically refutes false rumors of MHRA rejection and notes possible stock manipulation.","Rumors intensified after BNOS Annual Meeting where significant Phase 3 trial data were presented.","Company continues constructive interactions with MHRA; MAA progressing towards first regulatory decision."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-084743","json":"https://secwatch.observer/filing/0001104659-26-084743.json","markdown":"https://secwatch.observer/filing/0001104659-26-084743.md","text":"https://secwatch.observer/filing/0001104659-26-084743.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1072379/000110465926084743/0001104659-26-084743-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1072379/000110465926084743/tm2620800d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-20T10:05:40.678855+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}